Horizon Europe funded project ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise INnovative health technologies) is aiming to address the needs of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility of innovative health technologies (IHTs – including pharmaceuticals) in Europe. Affording many newly approved IHTs is challenging in many health systems.

Erasmus University Rotterdam is leading the project consortium alongside nine consortium partners: Comenius University Bratislava, Gesundheit Österreich GmbH, University of Oslo, Association Internationale de la Mutualité (AIM), Nuromedia GmbH, European Hematology Association (EHA), Chino SRL and OptiMedis. Myeloma Patients Europe (MPE) is a partner in the consortium and is representing the patient perspective throughout each work package.

ASCERTAIN will develop open-access, easy-to-use, policy-supporting tools, including:

• Pricing models
• Value assessment models
• Reimbursement models

These tools will be adaptable to country-specific conditions and patient preferences. A central aim is to improve the transparency and accountability of decision-making, reduce uncertainty for all stakeholders, reward innovation in areas of high unmet need, accelerate access for patients, and to support long-term planning and sustainability for healthcare systems. Furthermore, these tools will be developed, tested, and validated for three use cases, including precision cancer medicine, cell- and gene therapy, and medical devices or in vitro diagnostics.

For further information on Horizon Europe ASCERTAIN see here.

You can see the press release announcing the launch of the consortium here.